Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Second Order systems II01:18

Second Order systems II

409
In an underdamped second-order system, where the damping ratio ζ is between 0 and 1, a unit-step input results in a transfer function that, when transformed using the inverse Laplace method, reveals the output response. The output exhibits a damped sinusoidal oscillation, and the difference between the input and output is termed the error signal. This error signal also demonstrates damped oscillatory behavior. Eventually, as the system reaches a steady state, the error diminishes to zero.
409
First Order Systems01:21

First Order Systems

431
First-order systems, such as RC circuits, are foundational in understanding dynamic systems due to their straightforward input-output relationship. Analyzing their responses to different input functions under zero initial conditions reveals significant insights into system behavior.
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
431
Second Order systems I01:20

Second Order systems I

601
A servo system exemplifies a second-order system, featuring a proportional controller and load elements that ensure the output position aligns with the input position. The relationship between these components is described by a second-order differential equation. Applying the Laplace transform under zero initial conditions yields the transfer function, showing how inputs are converted to outputs in the system.
By reinterpreting the system, one can derive the closed-loop transfer function, which...
601

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating DNA Mutations and RNA Expression of Cancer Driver Genes in Asian Rare Cancers: A Pan-Cancer Analysis.

JCO precision oncology·2026
Same author

Age-related differences in outcomes and tumor characteristics of ultra-rare sarcomas: A Nation-wide Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026
Same author

Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Aristolochic Acid and Alternative Lengthening of Telomeres Mechanisms Underlie Liver Angiosarcoma Pathogenesis.

Liver cancer·2025
Same author

Prognostic significance of positive surgical margins for scalp angiosarcoma.

Journal of the Formosan Medical Association = Taiwan yi zhi·2025

Related Experiment Video

Updated: Feb 5, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

Next frontiers in systemic therapy for soft tissue sarcoma.

Cheuh-Chuan Yen1, Tom Wei-Wu Chen2

  • 1Division of Medical Oncology and Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.

Chinese Clinical Oncology
|September 4, 2018
PubMed
Summary
This summary is machine-generated.

New targeted therapies and immunotherapies are transforming soft tissue sarcoma (STS) treatment. This review explores molecular agents and immune checkpoint inhibitors (ICIs) for advanced STS.

Keywords:
Soft tissue sarcoma (STS)immunotherapymolecular targeted therapyprecision medicine

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Related Experiment Videos

Last Updated: Feb 5, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Soft tissue sarcoma (STS) is a complex cancer with over 50 subtypes.
  • Chemotherapy is the standard for advanced or metastatic STS.
  • Advances in understanding STS molecular and genomic mechanisms drive new drug development.

Purpose of the Study:

  • To review molecular targeted agents for STS.
  • To explore the role of immunotherapy in STS treatment.
  • To discuss precision medicine's impact on STS treatment paradigms.

Main Methods:

  • Review of molecular targeted agents including antiangiogenic molecules, PDGFRA monoclonal antibody, CSF-1R, SINE, CDK 4/6, mdm2, and epigenetic regulators.
  • Analysis of immunotherapies such as immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4.
  • Discussion of combination strategies and novel approaches like NY-ESO-1 targeting.

Main Results:

  • Molecular targeted therapies show promise by addressing specific genetic alterations in STS.
  • Immunotherapies, including ICIs, offer new avenues for solid tumor treatment, including STS.
  • Combination therapies and antigen-specific treatments are emerging strategies.

Conclusions:

  • Precision medicine is reshaping the treatment landscape for STS.
  • Targeted agents and immunotherapies represent significant advancements for advanced STS.
  • Further research into sarcoma and immune biology will likely revolutionize future STS treatment.